Cognition Therapeutics Inc
NASDAQ:CGTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ortel Communications Ltd
NSE:ORTEL
|
IN |
|
St Joe Co
NYSE:JOE
|
US |
Cognition Therapeutics Inc
Research & Development
Cognition Therapeutics Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cognition Therapeutics Inc
NASDAQ:CGTX
|
Research & Development
-$37.2m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Research & Development
-$15B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Research & Development
-$9.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Research & Development
-$10.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Research & Development
-$15.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Research & Development
-$13.3B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Cognition Therapeutics Inc
Glance View
Cognition Therapeutics, Inc. is a clinical stage neuroscience company. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 19 full-time employees. The company went IPO on 2021-10-08. The firm is engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. The company is focused on developing a pipeline of small molecule product candidates that targets the sigma-2 receptor (S2R) complex, a key regulator of the cellular damage response for diseases such as Alzheimer’s disease (AD), dry age-related macular degeneration (dry AMD), geographic atrophy (GA), and other conditions. Its lead product candidate, CT1812, an orally delivered, small molecule antagonist designed to penetrate the blood-brain and blood-retina barriers to the S2R complex, and through its modulation restores normal function of synapses, as well as critical cellular processes, such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling and receptor stabilization at the cell surface.
See Also
What is Cognition Therapeutics Inc's Research & Development?
Research & Development
-37.2m
USD
Based on the financial report for Dec 31, 2025, Cognition Therapeutics Inc's Research & Development amounts to -37.2m USD.
What is Cognition Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-24%
Over the last year, the Research & Development growth was 11%. The average annual Research & Development growth rates for Cognition Therapeutics Inc have been -7% over the past three years , -24% over the past five years .
